鞘氨醇-1-磷酸在肝纤维化研究中的进展

陈连云，，金欢欢，，陈琴，，张峰，，陆茵，，郑仕中，*

中国药学杂志 ›› 2014, Vol. 49 ›› Issue (15) : 1281-1284.

PDF(632 KB)
中国药学杂志
PDF(632 KB)
中国药学杂志 ›› 2014, Vol. 49 ›› Issue (15) : 1281-1284. DOI: 10.11669/cpj.2014.15.001
综述

鞘氨醇-1-磷酸在肝纤维化研究中的进展

  • 陈连云1，2，金欢欢1，2，陈琴1，2，张峰1，2，陆茵1，2，郑仕中1，2*
作者信息 +

Progress of Sphingosine-1-Phosphate in the Pathogenesis of Liver Fibrosis

  • CHEN Lian-yun1,2,JIN Huan-huan1,2, CHEN Qin1,2, ZHANG Feng1,2, LU Yin1,2, ZHENG Shi-zhong1,2*
Author information +
文章历史 +

摘要

目的 对近年来关于鞘氨醇-1-磷酸(sphingosine-1-phosphate，S1P)在肝纤维化中的作用及相关机制的研究做整理分析。方法 查阅近年来的国内外文献，进行全面综合、整理和归纳。结果 鞘氨醇-1-磷酸是一种具有生物活性的溶血磷脂，对肝纤维化的发生、发展和转归具有双重效应，这主要取决于其作用位点的不同。结论 鞘氨醇-1-磷酸在肝纤维化治疗中具有重要的作用，但作用机制复杂，有待更深入的研究。

Abstract

OBJECTIVE To analyze recent studies on the role of the sphingosine-1-phosphate (S1P) in liver fibrosis and related mechanism. METHODS By beading domestic and international documents in recent years. A comprehensive integrated progress was concluded. RESULTS S1P is a bioactive lysopholipid, studies show that S1P had a double effect on the development and regression of liver fibrosis, which mainly depended on its site of action. CONCLUSION S1P plays an important role in the treatment of liver fibrosis. But for its complex mechanism of action, further research need to be studied.

关键词

鞘氨醇-1-磷酸 / 肝纤维化 / 肝星状细胞 / 机制研究

Key words

sphingosine-1-phosphate / liver fibrosis / hepatic stellate cell / mechanism research

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
陈连云，，金欢欢，，陈琴，，张峰，，陆茵，，郑仕中，*. 鞘氨醇-1-磷酸在肝纤维化研究中的进展[J]. 中国药学杂志, 2014, 49(15): 1281-1284 https://doi.org/10.11669/cpj.2014.15.001
CHEN Lian-yun,,JIN Huan-huan,, CHEN Qin,, ZHANG Feng,, LU Yin,, ZHENG Shi-zhong,*. Progress of Sphingosine-1-Phosphate in the Pathogenesis of Liver Fibrosis[J]. Chinese Pharmaceutical Journal, 2014, 49(15): 1281-1284 https://doi.org/10.11669/cpj.2014.15.001
中图分类号： R965   

参考文献

[1] HUANG L, ZHANG M L. The effect of liguslrazine hydrochloride on hepatic stellate cell apoptosis and its possible mechanism. Chin Pharm J(中国药学杂志), 2013, 48(23):2013-2017.[2] SNIDER A J, ORR GANDY K A, OBEID L M. Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie, 2010, 92(6): 707-715.[3] MACEYKA M, HARIKUMAR K B, MILSTIEN S, et al. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol, 2012, 22(1): 50-60.[4] CALISE S, BLESCIA S, CENCETTI F, et al. Sphingosine-1-phosphate stimulates proliferation and migration of satellite cells: Role of S1P receptors. Biochim Biophys Acta, 2012, 1823(2): 439-450.[5] YANG L, YUE S, LIU X, et al. Sphingosine kinase/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J Hepatol, 2013, 59(1): 114-123.[6] LI C, YANG G, RUAN J. Sphingosine kinase-1/sphingosine-1-phosphate receptor type 1 signalling axis is induced by transforming growth factor-beta1 and stimulates cell migration in RAW264.7 macrophages. Biochem Biophys Res Commun, 2012, 426(3): 415-420.[7] BODE C, SENSKEN S C, PEEST U, et al. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem, 2010,109(6): 1232-1243.[8] TATEMATSU S, FRANCIS S A, NATARAJAN P, et al. Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine-1-phosphate-dependent signaling in vascular endothelium. Arterioscler Thromb Vasc Biol, 2013, 33(8): 1788-1794.[9] BAJWA A, HUANG L, YE H, et al. Dendritic cell sphingosine 1-phosphate receptor-3 regulates Th1-Th2 polarity in kidney ischemia-reperfusion injury. J Immunol, 2012, 189(5): 2584-2596. AWOJOODU A O, OGLE M E, SEFCIK L S, et al. Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis. Proc Natl Acad Sci USA, 2013, 110(34): 13785-13790. ALEMANY R, VAN KOPPEN C J, DANNEBERG K, et al. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol, 2007, 374(5-6): 413-428. WILKERSON B A, GRASS G D, WING S B, et al. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: High density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J Biol Chem, 2012, 287(53): 44645-44653. AUGE N, GARCIA V, MAUPAS-SCHWALM F, et al. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol, 2002, 22(12): 1990-1995. SCHAPER K, KIETZMANN M, BAUMER W. Sphingosine-1-phosphate differently regulates the cytokine production of IL-12, IL-23 and IL-27 in activated murine bone marrow derived dendritic cells. Mol Immunol, 2014, 59(1): 10-18. LI C, KONG Y, WANG H, et al. Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol, 2009, 50(6): 1174-1183. LI C, JIANG X, YANG L, et al. Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am J Pathol, 2009, 175(4): 1464-1472. SEREBROV V, KUZ'MENKO D I, BUROV P G, et al.Activity of the sphingomyelin cycle enzymes and concentration of products of sphingomyelin degradation in the rat liver in the course of acute toxic hepatitis. Biomed Khim, 2010, 56(2): 283-289. IKEDA H, WATANABE N, ISHII I, et al. Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2. J Lipid Res, 2009, 50(3): 556-564. LI C, ZHENG S, YOU H, et al. Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol, 2011, 54(6): 1205-1213. IKEDA H, OHKAWA R, WATANABE N, et al. Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. Clin Chim Acta, 2010, 411(9-10): 765-770. MANETTI M, GUIDUCCI S, MATUCCI-CERINIC M. The origin of the myofibroblast in fibroproliferative vasculopathy: Does the endothelial cell steer the pathophysiology of systemic sclerosis?. Arthritis Rheum, 2011, 63(8): 2164-2167. BRENNER D A, KISSELEVA T, SCHOLTEN D, et al. Origin of myofib-roblasts in liver fibrosis. Fibrogenesis Tissue Repair, 2012, 5(suppl 1):17. LIU Y, SAIYAN S, MEN T Y, et al. Hepatopoietin Cn reduces ethanol-induced hepatoxicity via sphingosine kinase 1 and sphingosine 1-phosphate receptors. J Pathol, 2013, 230(4): 365-376. KAGEYAMA Y, IKEDA H, WATANABE N, et al. Antagonism of sphingosine- 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents. Hepatology, 2012, 56(4): 1427-1438. LIU X, YUE S, LI C, et al. Essential roles of sphingosine-1-phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation. J Cell Physiol, 2011, 226(9): 2370-2377, 2011. ZHANG H, DESAI N N, OLIVERA A, et al. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J Cell Biol, 1991, 114(1): 155-167. DAVAILLE J, LI L, MALLAT A, et al. Sphingosine-1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J Biol Chem, 2002, 277(40): 37323-37330. IBRAHIM F B, PANG S J, MELENDEZ A J. Anaphylatoxin signaling in human neutrophils. A key role for sphingosine kinase. J Biol Chem, 2004, 279(43): 44802-44811. KEE T H, VIT P, MELENDEZ A J. Sphingosine kinase signalling in immune cells. Clin Exp Pharmacol Physiol, 2005, 32(3): 153-161. CHI H. Sphingosine-1-phosphate and immune regulation: Trafficking and beyond. Trends Pharmacol Sci, 2011, 32(1): 16-24. GOYAL P, BRUNNERT D, EHRHARDT J, et al. Cytokine IL-6 secretion by trophoblasts regulated via sphingosine-1-phosphate receptor 2 involving Rho/Rho-kinase and Rac1 signaling pathways. Mol Hum Reprod, 2013, 19(8): 528-538. ROSEN H, GONZALEZ-CABRERA P J, SANNA M G, et al. Sphingosine-1-phosphate receptor signaling. Annu Rev Biochem, 2009, 78: 743-768. CENCETTI F, BERNACCHIONI C, NINCHERI P, et al. Transforming growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation of sphingosine kinase-1/S1P3 axis. Mol Biol Cell, 2010, 21(6): 1111-1124. XIA P, WANG L, MORETTI P A, et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J Biol Chem, 2002, 277(10): 7996-8003. WANG X, ZHANG D M, GU T T, et al. Morin reduces hepatic inflammation-associated lipid accumulation in high fructose-fed rats via inhibiting sphingosine kinase 1/sphingosine- 1-phosphate signaling pathway. Biochem Pharmacol, 2013,86(12): 1791-1804. ROSENFELDT H M, HOBSON J P, MILSTIEN S, et al. The sphingosine-1-phosphate receptor EDG-1 is essential for platelet-derived growth factor-induced cell motility. Biochem Soc Trans, 2001, 29(Pt 6): 836-839. GOPARAJU S K, JOLLY P S, WATTERSON K R, et al. The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol Cell Biol, 2005, 25(10): 4237-4249. BRUNATI A M, TIBALDI E, CARRARO A, et al. Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures. Biochim Biophys Acta, 2008, 1783(3): 347-359. LIU Y, SAIYAN S, MEN T Y, et al. Hepatopoietin Cn reduces ethanol-induced hepatoxicity via sphingosine kinase 1 and sphingosine 1-phosphate receptors. J Pathol, 2013, 230(4):365-376. SUN B, PENG Z H, LIU G L. Application and mechanisms advance of immunosuppressant in organ transplantation . Chin Pharm J(中国药学杂志),2008,43(20):1530-1534. CHEN Z Q, CAO Y L, WANG Y. New oral drug for relapsing forms of multiple sclerosis—fingolimod . Chin Pharm J(中国药学杂志),2011,46(15):1215-1216.

基金

国家自然科学基金资助项目(81270514；30873424)；教育部博士点基金项目(20103237110010)；江苏省六大人才基金(2009-B-010)；江苏高校优势学科建设工程资助项目(ysxk-2010)；南京中医药大学中药学一级学科开放课题资助项目(2011ZYX4-008)；十一五科技支撑计划(2008BAI51B02)；江苏省2013年度普通高校研究生科研创新新计划项目(CXZZ13-06)
PDF(632 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉